415 related articles for article (PubMed ID: 33248510)
1. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
2. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
[TBL] [Abstract][Full Text] [Related]
5. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
[TBL] [Abstract][Full Text] [Related]
7. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
[TBL] [Abstract][Full Text] [Related]
8. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar.
Marquez LK; Chaillon A; Soe KP; Johnson DC; Zosso JM; Incerti A; Loarec A; Nguyen A; Walker JG; Mafirakureva N; Lo Re Iii V; Wynn A; McIntosh C; Kiene SM; Brodine S; Garfein RS; Vickerman P; Martin NK
BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33627360
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings.
Dziekan G; Chisholm D; Johns B; Rovira J; Hutin YJ
Bull World Health Organ; 2003; 81(4):277-85. PubMed ID: 12764494
[TBL] [Abstract][Full Text] [Related]
11. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
12. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
[TBL] [Abstract][Full Text] [Related]
13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
Mafirakureva N; Lim AG; Khalid GG; Aslam K; Campbell L; Zahid H; Van den Bergh R; Falq G; Fortas C; Wailly Y; Auat R; Donchuk D; Loarec A; Coast J; Vickerman P; Walker JG
J Viral Hepat; 2021 Feb; 28(2):268-278. PubMed ID: 33051950
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
16. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.
Hecht R; Hiebert L; Spearman WC; Sonderup MW; Guthrie T; Hallett TB; Nayagam S; Razavi H; Soe-Lin S; Vilakazi-Nhlapo K; Pillay Y; Resch S
Health Policy Plan; 2018 May; 33(4):528-538. PubMed ID: 29529282
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
19. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
Ward JW; Hinman AR
Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
Chhatwal J; He T; Hur C; Lopez-Olivo MA
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
